FRAZIER LIFESCIENCES ACQUISITION CORPORATION

Analyst Reco. Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

End-of-day quote Nasdaq Other stock markets 18:00:00 2024-05-14 EDT			5-day change	1st Jan Change
19.81 ^EUR	-3.37%		-9.38%	+77.35%

05-15	TD Cowen Starts NewAmsterdam Pharma With Buy Rating	MT
05-09	Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TD Cowen Starts NewAmsterdam Pharma With Buy Rating	05-15	MT
Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target	03-14	MT
RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk	02-29	MT
Guggenheim Starts NewAmsterdam Pharma With Buy Rating, $30 Price Target	01-18	MT
RBC Initiates NewAmsterdam Pharma at Outperform With Speculative Risk Qualifier, $25 Price Target	23-10-30	MT
Credit Suisse Lifts NewAmsterdam Pharma's Price Target to $22 From $21, Keeps Outperform Rating	23-04-03	MT
Credit Suisse Starts NewAmsterdam Pharma at Outperform With $21 Price Target	23-01-06	MT
SVB Securities Initiates Coverage on NewAmsterdam Pharma With Outperform Rating, $19 Price Target	22-12-20	MT
SVB Securities Starts NewAmsterdam Pharma at Outperform With $19 Price Target	22-12-20	MT
William Blair Starts NewAmsterdam Pharma at Outperform	22-12-19	MT
Jefferies Starts NewAmsterdam Pharma at Buy With $24 Price Target	22-12-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Stock Market
Equities
NAMS Stock
News Frazier Lifesciences Acquisition Corporation
Analyst Reco.

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW